QL1706 with chemotherapy induction followed by immunotherapy consolidation in limited-stage SCLC after chemoradiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial evaluates the safety and potential efficacy of QL1706, a bifunctional PD-1/CTLA-4 antibody, when combined with chemotherapy induction and followed by sequential immunotherapy consolidation in patients who have limited-stage SCLC after concurrent chemoradiotherapy. The study also explores biomarkers such as PD-L1, tumor mutational burden, and ctDNA to see if they correlate with treatment response and prognosis. Eligible participants are adults 18–75 with measurable LS-SCLC, good performance status, adequate organ function, and no significant interstitial lung disease. The trial is conducted at Shanghai Chest Hospital under lead sponsorship from Shanghai Chest Hospital, with no listed collaborators beyond the site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.
2. Pathologically confirmed LS-SCLC
3. Investigator confirmation of at least one measurable lesion, as defined by RECIST v1.1
4. ECOG performance status of 0 or 1
5. Forced expiratory volume in one second (FEV₁) \> 1.0 L
6. No clinically significant interstitial lung disease on baseline CT or PET/CT.
7. Adequate organ and bone-marrow function (all tests performed within 7 days prior to first dose; no transfusions, growth factors, albumin, or other corrective therapies within 14 days):Hemoglobin ≥ 90 g/L, ANC ≥ 1.5 × 10⁹/L, PLT ≥ 90 × 10⁹/L,Serum creatinine ≤ 1.5 × ULN, TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN, Albumin (ALB) ≥ 25 g/L,INR ≤ 1.5 × ULN, PT and APTT ≤ 1.5 × ULN (subjects on prophylactic anticoagulation must have values within a safe therapeutic range, per investigator)
8. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use reliable contraception from screening until 3 months after the last dose; male subjects must agree to use effective contraception or have undergone surgical sterilization for the same period.
9. No prior systemic anti-tumor therapy before enrollment.
10. Estimated life expectancy ≥ 12 weeks.

Exclusion Criteria:

1. Known hypersensitivity to QL1706 or any of its excipients
2. Histologically confirmed non-small cell lung cancer (NSCLC) or mixed tumor containing an NSCLC component.
3. History of another primary malignancy or previous allogeneic organ transplantation.
4. Surgery (other than diagnostic biopsy) within 4 weeks before first dose of study drug.
5. Active substance abuse (e.g., illicit drug use), chronic alcoholism, AIDS, or known HIV infection.
6. Active autoimmune disease, or history of autoimmune disease likely to recur. Systemic corticosteroid therapy equivalent to \>10 mg/day prednisone (or other immunosuppressive therapies) within 14 days before first dose.
7. Prior therapy with any antibody or agent targeting T-cell co-regulatory proteins (e.g., PD-1, PD-L1, CTLA-4, TIM-3, LAG-3).
8. Interstitial lung disease (ILD), or history of ILD requiring steroid therapy. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonia on screening chest CT.
9. Live vaccine administration within 28 days prior to first study drug dose. Any condition or comorbidity contraindicating chemo- or radiotherapy (e.g., active infection, myocardial infarction within 6 months, symptomatic heart disease including unstable angina, congestive heart failure, uncontrolled arrhythmia, ongoing immunosuppressive therapy).
10. Pregnant or breastfeeding women; women of childbearing potential or men unwilling to use adequate contraception.
11. Known hereditary bleeding diathesis or coagulation disorder.
12. Prior malignancy, except adequately treated non-melanoma skin cancer, or in situ carcinoma (e.g., breast, oral, cervical) with expected survival \>3 years.
13. Any other medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, could interfere with trial participation or interpretation of results.

Where it's running

• Shanghai Chest Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xuwei Cai
• Email: birdhome2000@163.com
• Phone: 02122200000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer

  This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with limited-stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06719700

• Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment

  This study is testing if combining a new immunotherapy drug with traditional chemoradiotherapy can help people with advanced esophageal cancer have better treatment results.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Anyang, Henan and 2 other locations · NCT06421376

• Audit of cervical cancer chemoradiation guideline compliance across National Cancer Grid centers

  This project will check how closely hospitals across India follow recommended chemoradiation treatments for patients with cervical cancer.

  Recruiting at 2 sites Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07290972

• Thiopegfilgrastim to prevent bone marrow suppression during chemoradiotherapy for esophageal or lung cancer

  This will try mecapegfilgrastim (a long-acting G-CSF) to prevent low neutrophil counts in adults with esophageal or lung cancer receiving concurrent chemoradiotherapy.

  Recruiting Phase 2 Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT07205536

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

• Toripalimab plus capecitabine after chemoradiotherapy for esophageal squamous cell carcinoma

  This trial will test whether giving toripalimab together with low‑dose capecitabine after definitive chemoradiotherapy helps people with locally advanced esophageal squamous cell carcinoma live longer and have fewer recurrences.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07177794

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.